Shots:
NICE has issued final draft guidance recommending Novartis’ Piqray (alpelisib) on the NHS for HR+, HER2-, PIK3CA-mutated LA, or metastatic breast cancer that has grown after treatment with combined hormonal therapy and a cancer growth inhibitor
NICE also recommended Gilead’s Trodelvy (sacituzumab govitecan) used for LA or metastatic TNBC that can’t be treated with surgery, after ≥2 lines of systemic therapies. Trodelvy will be available to patients in Wales and Northern Ireland
Since 2018, NICE has also maintained a 100% approval rate for breast cancer & reported that Piqray and Trodelvy are effective additional options to provide a better QoL for advanced breast cancer patients
Ref: NICE | Image: NICE
